Navigation Links
Promising Cystic Fibrosis Compound on Track for Development
Date:8/19/2007

Potential Therapy Made Possible by Early Investment by Cystic Fibrosis

Foundation

BETHESDA, Md., Aug. 15 /PRNewswire-USNewswire/ -- Gilead Sciences, Inc., one of the world's largest biopharmaceutical companies, and Parion Sciences, Inc., a development-stage pharmaceutical company, announced today they will co-develop Parion 680, a compound that could become an important new drug in treating the basic defect in cystic fibrosis. This product was identified as part of a $1.7 million award to Parion from Cystic Fibrosis Foundation Therapeutics, Inc. -- the CF Foundation's nonprofit drug discovery and development affiliate.

"This news validates our 'venture philanthropy' approach to drug development," said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. "We are a small disease, but as we have proven again and again, making the right investment in the early stages has an impact on how drugs are developed for cystic fibrosis. That is why the Foundation has been able to build a robust drug development pipeline that has nearly 30 promising therapies."

Parion 680 is intended to decrease the development of thick, sticky mucus in the lungs of CF patients, which often leads to severe infections that reduce lung function and cause irreversible lung damage.

A common condition in CF patients is the excessive absorption of sodium by affected cells, such as those lining the lungs, compounded by the inability of chloride to move swiftly out of these same cells. It is the net effect of both of these actions that gives rise to the thick tenacious secretions that eventually harbor the bacteria and create lung destruction. Compounds like Parion 680 try to remediate this condition by decreasing the CF cell's excessive absorption of sodium.

Gilead's commitment ensures that Parion 680 will be developed in a timely fashion for CF patients by a company that has sufficient resources to bring the
'/>"/>

SOURCE Cystic Fibrosis Foundation

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Ariana Smith, a 17-year-old Taylor teen, became the first patient ... a part of the Detroit Medical Center (DMC), and the ... a revolutionary 3D printed heart model to aid heart specialists ... In November, 2014, Ariana,s mom Jacqueline Foster ... a test that checks for problems with the electrical activity ...
(Date:3/31/2015)... ALPHARETTA, Ga. , March 31, 2015   ... Health Care, today announced it was awarded a new ... line of face masks. Effective March 1, 2015, Halyard,s ... masks with SO SOFT* lining, will be available to ... as well as 15,000 ambulatory surgery centers, physician practices ...
(Date:3/31/2015)... VICTORIA, BC , March 31, 2015 /CNW/ - T-Bird ... company focused on developing premium quality medical marijuana products ... the Marihuana for Medical Purposes Regulations ( Canada ... has received notice from The Corporation of the District ... rezoning approval of the Company,s premises which now allows ...
Breaking Medicine Technology:Taylor Teen Becomes First Patient in Michigan to Benefit From 3D Printed Heart Model to Treat Life-Threatening Aneurysm 2Taylor Teen Becomes First Patient in Michigan to Benefit From 3D Printed Heart Model to Treat Life-Threatening Aneurysm 3Taylor Teen Becomes First Patient in Michigan to Benefit From 3D Printed Heart Model to Treat Life-Threatening Aneurysm 4Taylor Teen Becomes First Patient in Michigan to Benefit From 3D Printed Heart Model to Treat Life-Threatening Aneurysm 5Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3
... 29, 2011 Professional and Trade Relations groups play ... to professional, payer and patient groups. However, today,s restrictive ... PTR activities - thus creating pressure on PTR groups ... optimize their impact.   Recognizing changing needs ...
... Centocor Ortho Biotech Products, L.P., today announced that ... for trabectedin for the treatment of women with recurrent ... U.S. Food and Drug Administration,s (FDA) recommendation that an ... The NDA was submitted to the FDA ...
Cached Medicine Technology:Professional Relations Excellence Outlined in New Best Practices, LLC Report 2Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin 2
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration ... forefront of using beard hair to fill in balding ... novelty has now become an absolute option for giving patients the ... do believe that beard to scalp hair transplant can be a ... isn’t as dense as we would like it,” says Dr. Parsa ...
(Date:3/31/2015)... Calling all runners, walkers and everyone who wants to join ... annual “Lyme Walk & Run” will be held Sunday, April ... hosted by Lyme Research Alliance (LRA) & Tick-Borne ... and education about Lyme and other tick-borne diseases. , ... feature 5K and 10K runs and one-mile and three-mile Walks ...
(Date:3/31/2015)... OnChip Devices , a world leader in Integrated ... chip targeted towards low voltage LED applications. Adding to its ... for protecting circuits by suppressing voltage higher than 3.0 Volts. ... up to 350W and 20A, providing protection of 8kV when ... These diodes do not exhibit any device degradation when compared ...
(Date:3/31/2015)... March 31, 2015 Dr. ... by the American Board of Dermatology and fellowship ... research training at the National Cancer Institute of ... his internship in internal medicine at the Emory ... Pennsylvania in Philadelphia. Dr. Li pursued further training ...
(Date:3/31/2015)... Dr. Uzma Parvez is having a busy start ... Grand Grounds Presentations at St. Michael’s Medical Center for attending ... The event was attended by a large gathering of ... feedback from the Grand Rounds. It was said that ... a while. , Ahead, Dr. Parvez has been invited ...
Breaking Medicine News(10 mins):Health News:Is Beard to Scalp Hair Transplant the Future? 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Dr. Andrew Li of Warren Skin Care Center Is Celebrating 3 Years Recognized as an "NJ Top Doc" 2Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2
... AEGON N.V.,and the international humanitarian organization Right ... the organization,s mission to help,children in deprived areas ... donated EUR 1 million as part of a ... Winter Olympic games in Vancouver, Canada., (Photo: ...
... benefit from further study of vitespen, researchers say , , ... vitespen didn,t increase recurrence-free survival among kidney cancer patients ... standard treatment for kidney cancer, but many patients are ... effective adjuvant treatment, according to background information in the ...
... at work, one expert says , , THURSDAY, July 3 (HealthDay ... man,s chances of developing erectile dysfunction, Finnish researchers report. , ... body. It,s what we in vascular surgery refer to as ... Sadeghi-Nejad, an associate professor of urology at UMDNJ New Jersey ...
... director of the National Alliance on Mental Illness ... the lives,of individuals and families affected by mental ... monitor the callous treatment and tragic death of,Ms. ... the psychiatric,ward at Kings County Hospital in Brooklyn, ...
... Renowned stroke researcher Dr. Vladimir Hachinski has been named ... for his lifetime contributions in the field of neurology. ... University of Western Ontario in the Department of Clinical ... Dentistry. He is the founding and current chairman ...
... is a condition that unexpectedly and unexplainably takes the lives ... year. Now researchers of the European Molecular Biology Laboratory in ... crib or cot death, which remains the leading cause of ... The model, published in this week,s issue of Science ...
Cached Medicine News:Health News:AEGON and Right To Play Announce Global Partnership 2Health News:AEGON and Right To Play Announce Global Partnership 3Health News:Kidney Cancer Vaccine Shows No Boost in Survival 2Health News:Lots of Sex May Prevent Erectile Dysfunction 2Health News:Kings County Death: NAMI Calls for Criminal Probe; Survey Shows Psychiatric Emergency Room Delays Are National Problem 2Health News:Pioneering stroke researcher awarded Canada's highest honor 2Health News:New research sheds light on the molecular basis of crib death 2
Ishihara test chart book for color blindness. 14 plate. A simple accurate method for discovering congenital color blindness....
10 plate suitable for children and the illiterate....
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Stainless steel disposable retinal MVR blade, 10 pcs / box....
Medicine Products: